30
CARDIOVASCULAR
hamburger

Broadest Expansion Range Among XIENCE™ Stents2

XIENCE Skypoint™ Stent has improved maximum expansion compared to previous generations, so interventional cardiologists (ICs) can use XIENCE™ Stents to treat a broader range of vessels.

Interventional cardiologists can expect better expansion with XIENCE Skypoint Stent.

Expansion up to 5.75 mm2

For ICs encountering larger vessels, this stent provides significant stent expansion: up to 5.75 mm when deploying 3.5-mm and 4.0-mm stents.

Smaller stents—2.0, 2.25, 2.5, 2.75, 3.0, 3.25 mm lengths—continue to expand to 3.75 mm.2

XIENCE Stent expands up to 5.75 mm for 3.5-mm and 4.0-mm stents, and smaller sizes expand up to 3.75 mm.

Even with greater expansion options, XIENCE™ stents exhibit no shortening.3 This can help to ensure accurate stent placement and reduce the risk of geographic miss, which has been reported in over 30% of percutaneous coronary interventions (PCI).4

No shortening, 3.5 x 18 mm stent deployed to 5.75 mm

XIENCE Skypoint™ Stent for Tapered Lesions

This stent exhibits excellent expansion and apposition for a wide range of vessel sizes while also delivering optimal patient outcomes.5 Moreover, treating long, tapered lesions is practical with a single stent, especially since the XIENCE Skypoint™ Stent is available in a 48-mm length.6

XIENCE Skypoint Stent can treat tapered vessels with a diameter of 3.5 mm up to 5.75 mm.

Small Tapered Vessels: Similarly, choosing a smaller diameter XIENCE Skypoint™ Stent allows ICs to treat a small tapered vessel, from 2.25 mm to 3.75 mm.6

XIENCE Skypoint Stent diameter sizes 2.00 to 3.75 mm can treat small tapered vessels with an expansion diameter up to 1.75 mm.

Better Longitudinal Strength

The XIENCE™ family of stents are built on the MULTI-LINK platform. Its 3 links per ring connect the peaks of one ring to the valleys of the adjacent ring. This prevents struts from either compressing together or stretching apart.

With the MULTI-LINK stent platform, XIENCE™ stents have better longitudinal strength, compared to other DES.7,8 This reduces the possibility of displacement or deformation for XIENCE Skypoint™ Stents.  

Compression tests reveal significantly improved longitudinal strength with XIENCE™ Stents compared to Synergy and Resolute Onyx DES.

 

XIENCE Stents perform better in longitudinal compression tests compared to Synergy and Resolute Onyx drug-eluting stents.

XIENCE Skypoint™ Stent Comparison: 3.0 mm x 48 mm8

Compression tests of 3.0 mm x 48 mm stents reveal excellent longitudinal strength with XIENCE Skypoint™ Stent—similar to XIENCE Xpedition™ Stent but significantly better than Synergy. So even when long lesions require PCI, the longitudinal strength of XIENCE Skypoint™ Stent sets it apart from other DES.

Using 48-mm stent lengths, XIENCE Skypoint Stent performs significantly better in longitudinal compression tests compared to Synergy DES; XIENCE Skypoint and XIENCE Xpedition results are the same.

Lower Crossing Profile on 48-mm Length9

For long lesions, the 48-mm XIENCE Skypoint™ Stent, compared to the XIENCE Xpedition™ Stent, is designed with narrower crests and tighter nesting. These features allow for a lower crossing profile of just 0.041”.

For long lesions, the 48-mm XIENCE Skypoint™ Stent is designed with narrow crest and tight nesting.

Better Expansion on 48-mm Length10

For long lesions, the 48-mm XIENCE Skypoint™ Stent’s design enhancements allow for improved expansion. Compared to the XIENCE Xpedition™ Stent, XIENCE Skypoint™ Stent is designed with elongated bar arms—offering better post-dilation (5.75 mm) expansion.

Together, all of these features lead to trusted patient outcomes, regardless of the diameter and length of the XIENCE Skypoint™ stent deployed.

The 48-mm XIENCE Skypoint™ Stent’s design enhancements allow for improved expansion.

  • Manuals & Technical Resources
  • Cardiovascular Products
  • Customer Service

References

  1. Zanchin C, et al. JACC Cardiovasc Interv. 2019;12(17):1665-1675. Serruys P, et al. N Engl J Med. 2010;363:136-146. Shiomi H, et al. JACC Cardiovasc Interv. 2019;12:637-647. Kufner S, et al. Circulation. 2019:139(3):325-333. Palmerini T, et al. Lancet. 2013;379:1393-1402. Bangalore S, et al. Circulation. 2012;125:2873-2891. Bangalore S, et al. Circ Cardiovasc Interv. 2013;6(6):378-390. Pilgrim T, et al. Lancet. 2014;384:2111-2122. Pilgrim T, et al. Lancet. 2018;392:737-746. Data on file at Abbott.
  2. XIENCE Skypoint™ IFU: XIENCE Skypoint™ Stent compared with XIENCE Sierra™ Stent, 3.5 x 18 mm stent expanded to 5.75 mm. Acceptance criterion allows 10% as maximum.
  3. Tests performed by and data on file at Abbott. Comparison is between XIENCE Skypoint™ Stent, Synergyand Resolute Onyx—3.5 x 18 mm or 20 mm stents tested and expanded to maximum labelled expansion limit.
  4. Calvert PA. Catheter Cardiovasc Interv. 2016;88(3):340-347.
  5. Sudhir K, et al. ISRN Cardiol. 2013:748736.
  6. XIENCE Skypoint™ IFU.
  7. Test performed by and data on file at Abbott. XIENCE Sierra™ Stent (5.0 x 33 mm) n=5, SYNERGY (5.0 x 32 mm) n=5, Resolute Onyx (5.0 x 33 mm) n=5.
  8. Test performed by and data on file at Abbott. XIENCE Skypoint™ Stent (3.0 x 48 mm) n=4, XIENCE Xpedition™ Stent (3.0 x 48 mm) n=5, SYNERGY (3.0 x 48 mm) n=3.
  9. Data on file at Abbott. Average stent profile: XIENCE Skypoint™ Stent 3.0 x 48 mm compared with XIENCE Xpedition™ Stent 3.0 x 48 mm.
  10. XIENCE Skypoint™ IFU. Data on file at Abbott. Note: Elongated bar arms is for medium stent design (9-crest design), 3.5 mm and 4.00 mm.
INDICATIONS, SAFETY & WARNINGS

MAT-2107572 v1.0

DO YOU WISH TO CONTINUE AND EXIT CARDIOVASCULAR.ABBOTT?

CONTENTS OF THE SITE ARE NOT UNDER THE CONTROL OF ABBOTT.

False
accessibility
© 2016 Abbott. All Rights Reserved. Please read the Legal Notice for further details.

Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company.

accessibility

DO YOU WISH TO CONTINUE AND EXIT CARDIOVASCULAR.ABBOTT?

CONTENTS OF THE SITE ARE NOT UNDER THE CONTROL OF ABBOTT.